Shopping Cart
- Remove All
- Your shopping cart is currently empty
YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations. It demonstrates notable antitumor efficacy, inducing tumor regression in EGFRex20ins-driven patient-derived xenograft (PDX) models [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,670 | 8-10 weeks | |
50 mg | $2,180 | 8-10 weeks | |
100 mg | $2,800 | 8-10 weeks |
Description | YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations. It demonstrates notable antitumor efficacy, inducing tumor regression in EGFRex20ins-driven patient-derived xenograft (PDX) models [1]. |
Molecular Weight | 500.6 |
Formula | C27H32N8O2 |
Cas No. | 2064269-82-3 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.